市场调查报告书
商品编码
1372027
全球桌上型蛋白质印迹处理器市场,到 2030 年的预测:按类型、应用和地区分類的全球分析Benchtop Western Blot Processor Market Forecasts to 2030 - Global Analysis By Type, Application and By Geography |
根据 Stratistics MRC 预测,2023 年全球桌上型蛋白质印迹处理器市场规模将达到 10.42 亿美元,预测期内年复合成长率为 8.2%,预计到 2030 年将达到 17.3689 亿美元。
蛋白质印迹是分子生物学、生物化学和免疫遗传学中常用的实验技术。此外,基本概念是用特异性抗体对将透过凝胶电泳处理的细胞和生物组织样本进行染色。透过分析染色的位置和深度,您可以更了解所检查的细胞和组织中特定蛋白质的表达。
根据《科学研究方法》,蛋白质印迹法,也称为蛋白质免疫印迹法,是一种广泛采用的技术,用于检测和分析复杂生物样品中的特定蛋白质。
随着生命科学领域(领域癌症生物学、神经科学和基因组学等领域)的迅速扩展,准确的蛋白质分析变得越来越必要。蛋白质印迹仍然是一项基本技术,因此桌上型处理器在这些研究领域至关重要。此外,桌上型处理器已成为研究人员最佳化蛋白质印迹程序以实现更高自动化、一致性和效率的主要因素。
即使有了最初的支出,持续的维护和运作成本也可能很困难。桌上型蛋白质印迹处理器需要定期维护、校准和替换凝胶、膜和抗体等消耗品。此外,车辆运作所需的电力和其他公用设施也增加了总成本。从长远来看,这些持续的成本可能会导致研究设施预算紧张。
科技的快速进步不断推动桌上型蛋白质印迹处理设备的创新。此外,製造商可以利用机会为这些设备添加更复杂的功能,例如自动化、更快的处理和更好的资料分析。在这个竞争激烈的市场中,公司可以透过开发用户友好的介面、云端基础的资料储存解决方案、远端监控等来使自己脱颖而出。
研究经费常常短缺,特别是在学术和非营利研究机构。预算限制是医疗保健部门面临的另一个问题。此外,桌上型蛋白质印迹处理器的初期成本可能很高,这可能会阻止或阻止潜在客户购买。医疗保健和研究方面的预算削减可能会对市场产生重大影响,并限制这些设备在不确定的经济状况下的使用。
桌上型蛋白质印迹处理器市场受到 COVID-19大流行的严重影响。由于全球供应链中断、研究设施暂时关闭以及将医疗资源分配给与疫情相关的活动,这些设备的采用速度已经放缓。由于财务限制和大流行的不可预测性,许多研究机构推迟了资本投资,例如新的桌上型蛋白质印迹处理器。然而,诊断测试的开拓以及蛋白质分析在 SARS-CoV-2 研究中的重要性导致了某些细分市场的持续需求。
预计蛋白质印迹系统市场将在半干印迹系统领域占据最大份额。这些系统受到实验室和研究人员的青睐,因为它们在速度和效率之间取得了良好的平衡。与传统的湿印迹系统相比,半干印迹可以用更少的缓衝液和实验室空间实现更快的转移。半干印迹结合了湿印迹方法和干印迹方法的优点。此外,该细分市场的受欢迎归因于其实惠的价格、快速的转移时间和易用性,使其成为许多蛋白质分析应用的首选。
製药和生物技术公司预计将在桌上型蛋白质印迹处理器市场中表现出最高的年复合成长率。这些公司定期资助的研发、药物研发和生物製造计划需要准确的蛋白质分析。对快速、可靠结果的需求以及这些行业日益增长的自动化趋势推动了对桌上型蛋白质印迹处理器的需求。该市场中製药和生物技术公司的高速成长归因于他们早期采用了先进的实验室设备。此外,个人化医疗和生技药品的进步正在推动蛋白质印迹应用的市场开拓,这些领域正在成为关键的成长动力。
一般来说,桌上型蛋白质印迹处理器市场预计将占据北美地区的最大份额。成熟的北美製药和生物技术产业、学术机构和诊断实验室需要这些仪器进行蛋白质研究和分析。此外,该地区也受惠于知名製造商、创新文化和雄厚的研究经费。这些因素的结合促成了北美桌上型蛋白质印迹处理器的压倒性市场占有率。
在桌上型蛋白质印迹处理器市场中,亚太地区的年复合成长率最高。这一增长的推动因素包括该地区学术研究机构数量的增加、生物技术和製药领域的增长以及生命科学研究投资的增加。此外,医疗保健行业的爆炸性增长和对先进实验技术认识的提高增加了对蛋白质印迹设备的需求。此外,亚太地区(尤其是中国和印度)不断变化的经济状况使该地区成为桌上型蛋白质印迹处理器市场的关键成长引擎。
According to Stratistics MRC, the Global Benchtop Western Blot Processor Market is accounted for $1000.42 million in 2023 and is expected to reach $1736.89 million by 2030 growing at a CAGR of 8.2% during the forecast period. In molecular biology, biochemistry, and immunogenetics, the western blot is a frequently used experimental technique. Moreover, the basic idea is to use particular antibodies to stain cells or biological tissue samples that are being processed through gel electrophoresis. Analyze the staining location and depth to learn more about the expression of particular proteins in the examined cells or tissues.
According to scientific research practices, Western blotting, also known as protein immunoblotting is a widely employed technique for detecting and analyzing specific proteins in complex biological samples.
Precise protein analysis is becoming more and more necessary as the life sciences sector-which includes fields like cancer biology, neuroscience, and genomics-expands quickly. Bench top processors are essential in these research domains because Western blotting is still a fundamental technique. Moreover, bench top processors are a major factor in the efforts of researchers to optimize the Western blotting procedure because they provide automation, consistency, and increased efficiency.
Even after the initial outlay, continuing upkeep and running costs can be difficult. Periodic maintenance, calibration, and replacement of consumables like gels, membranes, and antibodies are necessary for bench top Western blot processors. Additionally, the price of electricity and other utilities that are required for operation can also raise the total cost. Over time, these ongoing costs may put a strain on research facilities' budgets.
Bench top Western blot processor innovation is still being made possible by the rapid advancement of technology. Furthermore, manufacturers can take advantage of opportunities to add more sophisticated features to these instruments, like increased automation, quicker processing, and better data analysis. In this competitive market, companies can differentiate themselves by creating user-friendly interfaces, cloud-based data storage solutions, and remote monitoring.
Funding for research can be scarce, particularly in academic and nonprofit research organizations. Budgetary restrictions are another issue facing the healthcare sector. Moreover, bench top Western blot processors can be expensive up front, which could put off or discourage prospective customers from making a purchase. Budget cuts in healthcare and research can have a big effect on the market during uncertain economic times and limit the use of these instruments.
The market for bench top Western blot processors was greatly impacted by the COVID-19 pandemic. The adoption of these instruments slowed down as a result of disruptions to global supply chains, temporary closures of research facilities, and the allocation of healthcare resources to pandemic-related activities. A lot of labs postponed capital expenses because of financial limitations and the unpredictability of the pandemic, including buying new bench top Western blot processors. However, the development of diagnostic tests and the significance of protein analysis in the study of SARS-CoV-2 led to the persistence of demand in some market segments.
The Western blotting systems market is expected to have the largest share in the semi-dry blotting systems segment. These systems are well-liked by laboratories and researchers because they provide a good balance between speed and efficiency. Compared to conventional wet blotting systems, semi-dry blotting allows for faster transfers while using less buffer and laboratory space. Semi-dry blotting combines the benefits of both wet and dry blotting methods. Moreover, the popularity of this segment can be attributed to its affordability, quick transfer times, and user-friendliness, making it a favored choice for many protein analysis applications.
In the market for benchtop Western blot processors, pharmaceutical and biotechnology companies are anticipated to have the highest CAGR. Precise protein analysis is necessary for the R&D, drug discovery, and bio manufacturing initiatives that these companies regularly fund. The demand for bench top Western blot processors is driven by the need for quick and dependable results in these industries, as well as the growing trend toward automation. The high growth of pharmaceutical and biotechnology companies in this market can be attributed to their early adoption of sophisticated laboratory equipment. Furthermore, the development of Western blotting applications is being driven by advances in personalized medicine and biologics, which make these markets important growth drivers.
In general, the benchtop Western blot processor market is anticipated to hold the largest share in the North American region. The pharmaceutical and biotechnology industries, academic institutions, and diagnostic labs that are well-established in North America are the ones who need these instruments for research and analysis of proteins. Moreover, prominent manufacturers, a culture of technological innovation, and robust research funding are additional advantages for the region. North America holds a commanding market share in benchtop Western blot processors due to a combination of these factors.
In the market for benchtop Western blot processors, the Asia-Pacific area is growing at the highest CAGR. This growth is being driven by the region's growing number of academic and research institutions, growing biotechnology and pharmaceutical sectors, and rising investments in life sciences research. In addition, the need for Western blotting equipment has increased due to the healthcare industry's explosive growth and rising awareness of sophisticated laboratory techniques. Additionally, the changing economic conditions in the Asia-Pacific area, especially in China and India, have made the region a major growth engine for the market for benchtop Western blot processors.
Some of the key players in Benchtop Western Blot Processor market include: Bio-Rad Laboratories, Thermo Fisher Scientific, Bio-Techne, Merck, PerkinElmer, Gen Script Biotech, ATTO Corporation, Tecan, Life Technologies, Euroimmun, Precision Biosystems, Cytoskeleton, LI-COR Biosciences, Cytiva and Molecular Devices.
In July 2023, Bio-Rad Laboratories, Inc and QIAGEN N.V., announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.
In June 2023, Bio-Techne announced that it has reached an agreement to acquire Tolochenaz, Switzerland-based Lunaphore, a developer of fully automated spatial biology products. Bio-Techne said that it expects to close the deal by the end of September, in the first quarter of its fiscal 2024. Wenger Plattner is Bio-Techne's legal counsel. Bourgeois Avocat is legal counsel to Lunaphore, while UBS Investment Bank is Lunaphore's financial advisor.
In May 2023, Pfizer and Thermo Fisher Scientific Inc. announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable. Access to local NGS testing can help to provide faster analysis of associated genes, empowering healthcare providers to select the right therapy for that individual patient.